Interaction Between Cocaine and Quetiapine - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: July 13, 2004
Last updated: February 8, 2007
Last verified: March 2005
The purpose of this study is to assess the safety of intravenous (IV) cocaine in subjects taking quetiapine at 3 dosage levels.
Endpoint Classification: Safety Study
Primary Purpose: Treatment
||Interaction Between IV Cocaine and Quetiapine
Primary Outcome Measures:
- Adverse events
- pharmacokinetic assessment
| Estimated Enrollment:
| Study Start Date:
A placebo-controlled, double-blind, inpatient assessment of interaction between intravenous cocaine and quetiapine (seroquel) in cocaine-experienced subjects. To assess the safety of IV cocaine in subjects taking quetiapine at 3 dosage levels.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Includes but is not limited to: non-treatment seeking individuals. Must meet DSM-IV criteria for cocaine abuse or dependence. Must be able to verbalize understanding of consent and provide written informed consent and verbalize willingness to complete study procedures. Site will provide further details.
Please contact site for further information
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00087750
|Boston University Medical Center
|Boston, Massachusetts, United States, 02215 |
||Domenic Ciraulo, M.D.
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 13, 2004
||February 8, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 23, 2014
Central Nervous System Agents
Central Nervous System Depressants
Physiological Effects of Drugs